Even though the relative proportion of NSCLC bearing ALK rearrangements is significantly lower than ALCL or inflammatory myofibroblastic tumors (IMT), ALK-positive NSCLC represent overall the largest cohort of ALK-rearranged patients due the fact that lung cancer has a high incidence worldwide. The gene discussed is ALK; the disease is lung carcinoma.